New Pancreatic Cancer Drug Daraxonrasib Sparks High Demand in US
US cancer centers are experiencing a surge in patient requests for the experimental pancreatic cancer drug daraxonrasib. The drug, developed by Revolution Medicines, has shown promising results in clinical trials, doubling survival rates for patients with advanced pancreatic cancer. The FDA has approved an expanded access program, allowing patients to receive the drug while awaiting full approval. The drug targets a genetic mutation present in most pancreatic cancers and has extended median survival to 13.2 months compared to 6.7 months with standard chemotherapy. 
